|
期刊名称：BIOCHEMICAL PHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
Biochemical Pharmacology is an international journal which
Biochemical Pharmacology is an international journal which publishes research findings in pharmacology deriving from investigations that employ the disciplines of biochemistry, biophysics, molecular biology, genetics, structural biology, computer models and/or physiology. Behavioral pharmacology, neuropharmacology, cardiovascular pharmacology and molecular toxicology are also covered in the journal. Reports of studies with intact animals, organs, cells, subcellular components, enzymes or other cellular molecules and model systems are acceptable if they define mechanisms of drug action. Descriptive mathematical models including those involving computer techniques are also welcome. Experiments involving the use of drugs to elucidate biochemical, physiological and behavioral mechanisms in living organisms are also within the scope of the journal. In general, papers that record concentrations of drugs and metabolites in body fluids will only be accepted if they contribute to an understanding of biochemical and biophysical mechanisms. The Editors, however, reserve the right to publish any papers of major interest in the field. Only contributions in English will be considered or published.
The journal publishes the following types of communications
(1) Full-length Papers. These consist of a body of work presenting original findings relating to the question proposed by the investigators undertaking the research.
(2) Commentaries/Reviews are commissioned review articles (3000-5000 words in length). They are designed to be editorial statements on selected topics, and should not be exhaustive reviews. Primarily, such papers are intended to stimulate thought. They can be controversial, and can either focus on areas subject to much activity, or draw attention to relatively neglected fields in which there is both the opportunity and the need for research in biochemical pharmacology. Particularly welcome will be reviews in which authors present their personal view on the state of the subject on which they are reporting, and give their view as to where in the near or distant future the subject may be moving. Authors are especially encouraged to take issue with popular dogmas.
While the final decision on selection of authors for Commentaries/Reviews will be made by the Editor, suggestions from readers will be welcome. These should be addressed to: Professor J.E. Gielen, Universit?de Liège, Laboratoire de Chimie Medicale, Centre Hospitalier Universitaire, B-4000, Sart-Tilman par Liège, 1, Belgium. Fax: +32 4 3668823; e-mail: jgielen@chu.ulg.ac.be
Notes for Contributors can be found in all issues and Abbreviations in issues 1 and 7.
Please bookmark this URL: http://www.elsevier.com/locate/biochempharm
publishes research findings in pharmacology deriving from investigations that employ the disciplines of biochemistry, biophysics, molecular biology, genetics, structural biology, computer models and/or physiology. Behavioral pharmacology, neuropharmacology, cardiovascular pharmacology and molecular toxicology are also covered in the journal. Reports of studies with intact animals, organs, cells, subcellular components, enzymes or other cellular molecules and model systems are acceptable if they define mechanisms of drug action. Descriptive mathematical models including those involving computer techniques are also welcome. Experiments involving the use of drugs to elucidate biochemical, physiological and behavioral mechanisms in living organisms are also within the scope of the journal. In general, papers that record concentrations of drugs and metabolites in body fluids will only be accepted if they contribute to an understanding of biochemical and biophysical mechanisms. The Editors, however, reserve the right to publish any papers of major interest in the field. Only contributions in English will be considered or published.
The journal publishes the following types of communications
(1) Full-length Papers. These consist of a body of work presenting original findings relating to the question proposed by the investigators undertaking the research.
(2) Commentaries/Reviews are commissioned review articles (3000-5000 words in length). They are designed to be editorial statements on selected topics, and should not be exhaustive reviews. Primarily, such papers are intended to stimulate thought. They can be controversial, and can either focus on areas subject to much activity, or draw attention to relatively neglected fields in which there is both the opportunity and the need for research in biochemical pharmacology. Particularly welcome will be reviews in which authors present their personal view on the state of the subject on which they are reporting, and give their view as to where in the near or distant future the subject may be moving. Authors are especially encouraged to take issue with popular dogmas.
While the final decision on selection of authors for Commentaries/Reviews will be made by the Editor, suggestions from readers will be welcome. These should be addressed to: Professor J.E. Gielen, Universit?de Liège, Laboratoire de Chimie Medicale, Centre Hospitalier Universitaire, B-4000, Sart-Tilman par Liège, 1, Belgium. Fax: +32 4 3668823; e-mail: jgielen@chu.ulg.ac.be
Notes for Contributors can be found in all issues and Abbreviations in issues 1 and 7.
Please bookmark this URL: http://www.elsevier.com/locate/biochempharm |
|
Instructions to Authors
|
Submission of Manuscripts
For the initial submission of manuscripts for consideration, hardcopies are sufficient. The original plus two copies, complete with two sets of figures (including originals or duplicates of sufficient quality for clarity of reproduction) and tables, must be submitted in English. All data that would help referees to evaluate the paper should also be supplied. Manuscripts should be typewritten with double spacing and adequate margins on one side of the sheet only (not more than 26 lines per page). All pages should be numbered sequentially. Manuscripts should be sent to the Editor-in-Chief. Please include full contact information - corresponding author name, e-mail address, telephone and fax numbers, and full postal address.
All papers should be sent to the Editor-in-Chief: Professor Jacques E. Gielen, Universit?de Liège, Laboratoire de Chimie Medicale, Centre Hospitalier Universitaire, B-4000, Sart-Tilman par Liège, 1, Belgium. Fax: +32 4 3668823; e-mail: jgielen@chu.ulg.ac.be,
Commentaries and Reviews: Suggestions from readers of topics and authors will be welcome. When readers suggest topics, they will normally be asked to submit a brief outline of the proposed Commentary/Review. A decision to commission the Commentary/Review will be made as rapidly as possible after receipt of these outlines.
The Editors welcome submission by the authors of the names, addresses, telephone and FAX numbers of 5 or 6 individuals who could, in their opinion, expertly review their submitted manuscript. The Editors, of course, reserve the right to use reviewers of their choice. An assurance should be given that the material has not been published or submitted elsewhere.
After final acceptance for publication, your revised manuscript on disk together with two printed hard copies, should be submitted to the Editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the Editor to Elsevier.
Form of Contributions
All papers should be submitted in English with an abstract summarizing briefly the essential contents. (For further details on the format of the abstract, see next section.) An original and three copies of the manuscript (including figure captions and references) should be sent, and text should be typed on one side of the paper, double-spaced and with margins. The form generally accepted by learned societies should be followed: Abstract, Introduction (with no heading), Materials and Methods, Results and Discussion. Manuscripts must be accompanied by copies of all relevant articles that are cited as in press or under consideration by another journal.
Commentaries/Reviews are research editorials. An abstract must be included; details are given below.
For abstracting purposes, please include the first name of each author of a paper to be published in the journal. In addition, 6 keywords or short phrases should be added at the bottom of the abstract page to assist in indexing the article and which may be published with the Abstract. Use terms from the Subject Headings from Index Medicus where possible. The original manuscript and diagrams will be discarded 1 month after publication unless the publisher is requested to return original material to the author. Contributors are requested to indicate clearly on the title page of the manuscript the name, mailing address, telephone number, fax number, and email address, if available, of the author to whom proofs and correspondence should be sent.
After final acceptance for publication, your revised manuscript must be submitted on disk, together with two identical printed hard copies, to the accepting Editor. It is important that the file on disk and the printed copies be identical. Electronic files can be submitted on floppy disks, ZIP/JAZ disks, or CD-ROM. Please do not split the manuscript into separate files (title page as one file, text as another, etc.) Ensure that the letter 'l' and digit '1'(also letter 'O' and digit '0') have been used properly, and format your article (tabs, indents, etc.) consistently. Characters not available on your word processor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g, gralpha, @, #, etc., for the Greek letter  ). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your word processor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the word processor format. If your wordprocessor features the option to save files 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used, label the disk with your name and the name of the file on disk.
Additional instructions on how to prepare your manuscript can be found at: http://authors.elsevier.com/quickguide. More in-depth guidelines for submitting artwork/illustrations can be found at: http://authors.elsevier.com/artwork.
Classification
Authors are requested to classify their papers at the time of submission in one of the following categories:
(1) Molecular and Cellular Pharmacology
(2) Chemotherapy and Metabolic Inhibitors
(3) Neuroscience
(4) Hormones and Growth Factors
(5) Gene Expression and Development
(6) Structural Biology
(7) Inflammation and Immunopharmacology
(8) Cardiovascular and Pulmonary Pharmacology
(9) Gastrointestinal and Renal Pharmacology
The category chosen should be listed on the title page. Commentaries will continue to be listed in a separate category.
Abstracts
Research Papers. The abstract, which must be a maximum of 250 words in length, should contain (a) a clear statement of the aims of the study or hypothesis that the study is designed to test, (b) a short summary of the major methodological approach, (c) a detailed summary, including wherever possible numerical and statistical data, of the results, and (d) a one- or two-sentence statement of the major conclusions of the research.
Commentaries/Reviews must be accompanied by an abstract, which should be a maximum of 250 words in length and contain (a) a clear statement of the aim of the paper, (b) a summary of the major points of information contained within the paper, and (c) a one- or two-sentence statement of the major conclusions arising from the paper.
Authors are reminded that the title and abstract of their manuscript are extracted in isolation by commercial abstracting services and, therefore, should contain all important information presented within the manuscript.
Nomenclature and Abbreviations
Where possible, nomenclature and abbreviations should be in accord with internationally agreed rules. When an enzyme or compound is first mentioned in the text, specification by its code number accompanied by its systematic name (as distinct from its trivial name) is requested by the Editors, but not checked for correctness. Official names of drugs are preferred to trade names. If trade names are used, they should be capitalized and the trademark included. When listing the source from which a compound is obtained, give both the name and location of the company.
It is necessary that the abbreviations used in the main text should be defined in a footnote on the title page of the article. Abbreviations used in the Abstract must be defined within the Abstract as this must be comprehensible without consulting the main text. Abbreviations, including internationally accepted biochemical abbreviations, that can be used without definition, except in titles, can be found in issues 1 and 7 of each volume.
The mass of a biochemical entity should be specified as either relative molecular mass (Mr, not molecular weight) or as molecular mass (expressed in kDa). Mr should not be expressed in daltons. Use either Mr or kDa consistently throughout a paper.
The source of the cell lines employed in studies should be indicated, as well as information on the quality control of the lines employed in the investigations.
Temperatures denoted by an unqualified degree symbol  are assumed to be Centigrade. For solution strengths, percentages should be expressed by the sign %, followed in cases of ambiguity by w/w, w/v or v/v [e.g. 5% (w/v) means 5 g/100 mL]. In spectrophotometry, extinction (E) should be used, rather than optical density.
Statements with regard to statistical significance should be accompanied by probability values derived from appropriate statistical tests.
The following sources give useful guidance on the preparation of manuscripts:
1. Suggestions and Instructions to Authors, Biochem J 329: 1-16, 1998. It is particularly requested that authors follow the instructions on isotopically labeled compounds.
2. Terminology and Abbreviations, J Biol Chem 269: 777-785, 1994.
3. International Union of Biochemistry, Enzyme Nomenclature. Academic Press, 1992.
4. CBE Style Manual Committee, Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers, 6th Edn., Council of Biology Editors, Inc., Chicago, IL 60603.
Figures and Tables
Figures
Line drawings (including graphs) should be drawn in black ink on white paper or on tracing paper with blue or faint grey rulings; graduation will not be reproduced. Lettering should be large enough to permit photographic reduction. If figures are not to be reduced, their format should not exceed 16 x 20 cm. Photographs (or half-tone illustrations) must be of good quality, submitted as black and white prints on glossy paper, and have as much contrast as possible. The magnification of micrographs should be indicated by a scale bar in the figure. Figures should be clearly marked on the reverse side with the number, orientation (top) and author's name; a soft pencil or a felt-tipped pen should be used for marking photographs. The illustrations should be numbered with Arabic numerals. The legends should be typed separately with double spacing.
Tables
All tables must be numbered consecutively (with Arabic numerals) and be cited in the text. Titles should be short but descriptive. Tables should be compiled on separate sheets, together with a legend and/or footnotes identified by superscripts a.b.c, etc. Do not use vertical lines and keep horizontal rules to a minimum.
Reproduction of Photographs
Black and White photographs
These should be presented in the form of good quality glossy prints
Colour Photographs
Colour photographs, such as histochemical sections can be reproduced in colour, but a charge relating to the reproduction of material in colour may be assessed. An estimate of any charge can be obtained from the publishers.
If, together with your accepted article, you submit usable colour figures then Elsevier will ensure, at no additional charge, that these figures will appear in colour on the web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version. For colour reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. For further information on the preparation of electronic artwork, please see http://authors.elsevier.com/artwork.
Please note: Because of technical complications which can arise by converting colour figures to 'grey scale'(for the printed version should you not opt for colour in print) please submit in addition usable black and white prints corresponding to all the colour illustrations.
Colour illustrations
Submit colour illustrations as original photographs, high-quality computer prints or transparencies, close to the size expected in publication, or as 35 mm slides. Polaroid colour prints are not suitable. If, together with your accepted article, you submit usable colour figures then Elsevier will ensure, at no additional charge, that these figures will appear in colour on the web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version.
For colour reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. For further information on the preparation of electronic artwork, please see http://authors.elsevier.com/artwork.
Please note: Because of technical complications which can arise by converting colour figures to 'grey scale' (for the printed version should you opt to not pay for colour in print) please submit in addition usable black and white prints corresponding to all the colour illustrations.
As only one figure caption may be used for both colour and black and white versions of figures, please ensure that the figure captions are meaningful for both versions, if applicable. References
References should be numbered consecutively in square brackets in the text, the full reference being cited in a numbered list at the end of the paper. References should contain the names and initials of all the authors of each paper, together with the full title of the paper, the abbreviated journal title, the the year, the volume number, and the first and last page numbers. Formatting samples are given below:
Journal
[1] Reiter R, Burk RF, Effect of oxygen tension on the generation of alkanes and malondialdehyde by peroxidizing rat liver microsomes. Biochem Pharmacol 1987;36: 925-9.
Book
[2] Winer BJ, Statistical Principles in Experimental Design.New York: McGraw-Hill, 1971.
Chapter in a book
[3] Shatkin AJ, Colorimetric reactions for DNA, RNA, and protein determinations. In: Habel K and Salzman NP. editors. Fundamental Techniques in Virology. New York: Academic Press, 1969. pp. 231-7.
Symposium proceedings [4] Wefers H , Sies H, Generation of photoemissive species during quinone redox cycling. In: Alexander P, editor. Bioreduction in the Activation of Drugs, Proceedings of the Second Biochemical Pharmacology Symposium, Oxford, UK, 25-26 July 1985. Oxford: Pergamon Press, 1986. pp. 22-4.
The titles of journals should be abbreviated in accordance with Index Medicus.
Footnotes
Footnotes, as distinct from literature references, should be indicated by superscript arabic numerals: 1, 2, 3, numbered continuously throughout the text. They should not be included in the numbered reference system. Footnotes should be used for references to unpublished work (including work submitted for publication), personal communications (the wording of the quoted material should be verified with the person who supplied the information, and a letter of permission to use this material must be obtained from the source and submitted), proprietary names of trademarked drugs and other material not appropriately referred to in the text or in the numbered reference list, but should be kept to a minimum. Symbols indicating author affiliations should be superscript letters: a, b, c, with an asterisk to indicate the corresponding author of the manuscript.
Proofs, Offprints and Page Charges
Proofs
Elsevier is now sending PDF proofs to authors by e-mail for correction. If an author is unable to handle this process, regular print proofs will be sent. Elsevier will do everything possible to get the article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all corrections are sent back in ONE communication. Subsequent corrections will not be possible. Only typesetting errors may be corrected; no changes in, or additions to, the accepted manuscript will be allowed. Proofs should be returned to Elsevier within 48 hours.
Offprints
Upon acceptance, an offprint order form will be sent to the author(s) together with proofs. Offprints may be ordered by filling in and returning to the Publisher the order form sent to the authors with the proofs of their paper. Twenty-five offprints of each paper will be provided free of charge. Additional copies may be ordered at prices shown on the offprint order form which will be sent to the author. Offprints ordered after the journal has been printed will cost considerably more than those ordered immediately.
Page Charges
There will be no page charges.
Author enquiries
All questions arising after acceptance of the manuscript by the editors, especially those relating to proofs, publications and reprints should be directed to the Publisher:
Elsevier Ireland Ltd.
Brookvale Plaza
East Park
Shannon, Co. Clare
Ireland
Tel: +353 61 709600
Fax: + 353 61 709100
E-mail: authorsupport@elsevier.com
Please visit the Elsevier Author Gateway at http://authors.elsevier.com to track accepted articles and set up e-mail alerts to inform you of when the article status has changed. Information on artwork guidelines, copyright information, and frequently asked questions is also available.
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances made in the medical sciences, independent verification of diagnoses and drug dosages should be made.
| |
Editorial Board
- Editor-in Chief:
- J.E. Gielen, Universit?de Liège, Laboratoire de Chimie Médicale, Centre Hospitalier Universitaire, B-4000, Sart-Tilman par Liège 1, Belgium; Fax: (32)4-366-8823, Email: jgielen@chu.ulg.ac.be
- Associate Editor:
- J. Piette, Universite de Liège, Laboratoire de Virologie, Institut de Pathologie, Liège, Belgium; Fax: (32)4-366-2433, Email: jpiette@ulg.ac.be
- Editorial Advisory Board:
- J. Aarbakke, University of Tromso, Tromso, Sweden
C. Bailly, IRCL, Lille, France
P.H. Beaune, University Rene Descartes, Paris, France
K.W. Bock, Tübingen University, Tübingen, Germany
A.R. Boobis, Hammersmith Hospital, London, UK
M. Cascales, Universidad Complutense, Madrid, Spain
C.E. Cass, University of Alberta, Edmonton, Alberta, Canada
Y.-N. Cha, Inha University, Inchon, South Korea
R.A.J. Challiss, University of Leicester, Leicester, UK
M.M.-Y. Chan, Temple University, Philadelphia, PA, USA
M.S. Chen, Plantaceutica Inc., Research Triangle Park, NC, USA
Z. Chen, Chinese Academy of Sciences, Beijing, China
E. Chu, VA Medical Center, West Haven, CT, USA
I. Creese, State University of New Jersey, Newark, NJ, USA
E. Declerq, Catholic University of Leuven, Leuven, Belgium
D.G. Deutsch, State University of New York at Stony Brook, Stony Brook, NY, USA
M. Diederich, Centre Universitaire de Luxembourg, Luxembourg
B. Dolnick, Roswell Park Cancer Institute, Buffalo, NY, USA
J. Elsworth, Yale University School of Medicine, New Haven, CT, USA
S. Eriksson, `Swedish University of Agriculture, Uppsala, Sweden
J.N. Fain, University of Tennessee, Memphis, TN, USA
J. Frere, Universit?de Liège, Liège, Belgium
R. Ganapathi, Taussig Cleveland Cancer Center, Cleveland, OH, USA
T.A. Gasiewicz, University of Rochester, Rochester, NY, USA
R.I. Glazer, Georgetown University, Washington, DC, USA
I.D. Goldman, Albert Einstein College of Medicine, Bronx, NY, USA
F.J. Gonzalez, National Cancer Institute, Bethesda, MD, USA
S. Grant, Virginia Commonwealth University, Richmond, VA, USA
F.P. Guengerich, Vanderbilt University School of Medicine, Nashville, TN, USA
K.-I. Inui, Kyoto University Hospital, Kyoto, Japan
J.-K. Lin, National Taiwan University, Taipei, Taiwan ROC
P. MacKenzie, Flinders University Medical Centre, Bedford Park, Australia
N.J. MacLusky, Columbia University Medical School, New York, NY, USA
F. Matsumura, University of California, Davis, CA, USA
J. Meldolesi, University of Milan, Milan, Italy
N. Miki, Osaka University School of Medicine, Osaka, Japan
J. Moreno, Barcelona University, Barcelona, Spain
J.F. Nagelkerke, University of Leiden, Leiden, The Netherlands
N.H. Neff, Ohio State University, Columbus, OH, USA
H. Nohl, Veterinary University of Vienna, Austria
A.B. Okey, University of Toronto, Ontario, Canada
C.J. Omiecinski, Penn State University, University Park, PA, USA
C.R. Pace-Asciak, Hospital for Sick Children, Toronto, ON, Canada
L. Packer, University of Southern California, Los Angeles, CA, USA
B.K. Park, Liverpool University, Liverpool, UK
W.B. Parker, Southern Research Institute, Birmingham, AL, USA
J. Pierre, Universit?Paris XI, Chatenay-Malabry, France
G. Pizzorno, Yale University School of Medicine, New Haven, CT, USA
A. Puga, University of Cincinnati Medical Center, Cincinnati, OH, USA
E. Richelson, Mayo Clinic, Jacksonville, FL, USA
A.B. Rifkind, J. & S. Weill Medical College, New York, NY, USA
J.A. Roth, State University of New York, Medical Center, Buffalo, NY, USA
E.A. Sausville, National Cancer Institute, Rockville, MD, USA
A. Schousboe, Royal Danish School of Pharmacy, Copenhagen, Denmark
K. Schulze-Osthoff, University of Münster, Münster, Germany
W.C. Sessa, Yale University School of Medicine, New Haven, CT, USA
P.R. Sinclair, VA Research, White River Junction, VT, USA
T. Skovsgaard, University of Copenhagen, Herlev, Denmark
B. Teicher, Genzyme Corporation, Framingham, MA, USA
B. Testa, University of Lausanne, Lausanne, Switzerland
K.D. Tew, Fox Chase Cancer Center, Philadelphia, PA, USA
K. Tipton, University of Dublin, Dublin, Ireland
A.J. Townsend, Wake Forest University, Winston-Salem, NC, USA
D.J. Triggle, State University of New York, Buffalo, NY, USA
V. Ullrich, Universität Konstanz, Konstanz, Germany
N.P.E. Vermeulen, Free University, Amsterdam, The Netherlands
P. Waldmeier, Ciba-Geigy Ltd, Basel, Switzerland
D.J. Waxman, Boston University School of Medicine, Boston, MA, USA
H. Weiner, Purdue University, West Lafayette, IN, USA
P. Workman, Institute of Cancer Research, Sutton, UK
M.B.H. Youdim, Technion-Israel Institute of Technology, Haifa, Israel
F. Zunino, Ist. Naz. per lo Studio e la Cura dei Tumori, Milan, Italy
|
|
|
|
